136 related articles for article (PubMed ID: 36082616)
1. First-in-human study of ONO-4578, an antagonist of prostaglandin E
Iwasa S; Koyama T; Nishino M; Kondo S; Sudo K; Yonemori K; Yoshida T; Tamura K; Shimizu T; Fujiwara Y; Kitano S; Shimomura A; Sato J; Yokoyama F; Iida H; Kondo M; Yamamoto N
Cancer Sci; 2023 Jan; 114(1):211-220. PubMed ID: 36082616
[TBL] [Abstract][Full Text] [Related]
2. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.
Heinhuis KM; Carlino M; Joerger M; Di Nicola M; Meniawy T; Rottey S; Moreno V; Gazzah A; Delord JP; Paz-Ares L; Britschgi C; Schilder RJ; O'Byrne K; Curigliano G; Romano E; Patah P; Wang R; Liu Y; Bajaj G; Siu LL
JAMA Oncol; 2020 Jan; 6(1):100-107. PubMed ID: 31697308
[TBL] [Abstract][Full Text] [Related]
3. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
5. OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.
Gutierrez M; Moreno V; Heinhuis KM; Olszanski AJ; Spreafico A; Ong M; Chu Q; Carvajal RD; Trigo J; Ochoa de Olza M; Provencio M; De Vos FY; De Braud F; Leong S; Lathers D; Wang R; Ravindran P; Feng Y; Aanur P; Melero I
Clin Cancer Res; 2021 Jan; 27(2):460-472. PubMed ID: 33148673
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
Kanda S; Goto K; Shiraishi H; Kubo E; Tanaka A; Utsumi H; Sunami K; Kitazono S; Mizugaki H; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Hozumi H; Tamura T
Ann Oncol; 2016 Dec; 27(12):2242-2250. PubMed ID: 27765756
[TBL] [Abstract][Full Text] [Related]
7. First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Yarchoan M; Powderly JD; Bastos BR; Karasic TB; Crysler OV; Munster PN; McKean MA; Emens LA; Saenger YM; Ged Y; Stagg R; Smith S; Whiting CC; Moon A; Prasit P; Jenkins Y; Standifer N; Dubensky TW; Whiting SH; Ulahannan SV
Cancer Res Commun; 2024 Apr; 4(4):1100-1110. PubMed ID: 38551394
[TBL] [Abstract][Full Text] [Related]
8. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of the
Kim C; Liu SV; Subramaniam DS; Torres T; Loda M; Esposito G; Giaccone G
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616557
[TBL] [Abstract][Full Text] [Related]
10. First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE
Hong DS; Parikh A; Shapiro GI; Varga A; Naing A; Meric-Bernstam F; Ataman Ö; Reyderman L; Binder TA; Ren M; Liu M; Dayal S; Siu AY; Sachdev P; Xu L; Bhagawati-Prasad V; Tchakov I; Ooi CE; Bao X; Marabelle A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554609
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
[TBL] [Abstract][Full Text] [Related]
12. Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C.
Yoh K; Hirashima T; Saka H; Kurata T; Ohe Y; Hida T; Mellemgaard A; Verheijen RB; Ou X; Ahmed GF; Hayama M; Sugibayashi K; Oxnard GR
Target Oncol; 2021 May; 16(3):339-355. PubMed ID: 33939068
[TBL] [Abstract][Full Text] [Related]
13. TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704).
Kawazoe A; Itahashi K; Yamamoto N; Kotani D; Kuboki Y; Taniguchi H; Harano K; Naito Y; Suzuki M; Fukutani M; Higuchi T; Ikeno T; Wakabayashi M; Sato A; Koyama S; Nishikawa H; Shitara K
Clin Cancer Res; 2021 Dec; 27(24):6709-6715. PubMed ID: 34593531
[TBL] [Abstract][Full Text] [Related]
14. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
15. An EP4 antagonist ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer.
Xu S; Zhang Z; Ogawa O; Yoshikawa T; Sakamoto H; Shibasaki N; Goto T; Wang L; Terada N
Cell Biochem Biophys; 2014 Sep; 70(1):521-7. PubMed ID: 24744183
[TBL] [Abstract][Full Text] [Related]
16. A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.
Mettu NB; Ulahannan SV; Bendell JC; Garrido-Laguna I; Strickler JH; Moore KN; Stagg R; Kapoun AM; Faoro L; Sharma S
Clin Cancer Res; 2022 Mar; 28(5):882-892. PubMed ID: 34844977
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Rizvi NA; Hellmann MD; Brahmer JR; Juergens RA; Borghaei H; Gettinger S; Chow LQ; Gerber DE; Laurie SA; Goldman JW; Shepherd FA; Chen AC; Shen Y; Nathan FE; Harbison CT; Antonia S
J Clin Oncol; 2016 Sep; 34(25):2969-79. PubMed ID: 27354481
[TBL] [Abstract][Full Text] [Related]
18. Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies.
Saka H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Horinouchi H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Yada N; Tamura T
Jpn J Clin Oncol; 2021 Jan; 51(1):106-113. PubMed ID: 33020837
[TBL] [Abstract][Full Text] [Related]
19. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
Niu J; Maurice-Dror C; Lee DH; Kim DW; Nagrial A; Voskoboynik M; Chung HC; Mileham K; Vaishampayan U; Rasco D; Golan T; Bauer TM; Jimeno A; Chung V; Chartash E; Lala M; Chen Q; Healy JA; Ahn MJ
Ann Oncol; 2022 Feb; 33(2):169-180. PubMed ID: 34800678
[TBL] [Abstract][Full Text] [Related]
20. A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.
Choueiri TK; Atkins MB; Rose TL; Alter RS; Ju Y; Niland K; Wang Y; Arbeit R; Parasuraman S; Gan L; McDermott DF
Invest New Drugs; 2021 Aug; 39(4):1019-1027. PubMed ID: 33507454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
